# A Study of SGN-B6A in Chinese Participants With Advanced Solid Tumors

> **NCT06549816** · PHASE1 · COMPLETED · sponsor: **Seagen, a wholly owned subsidiary of Pfizer** · enrollment: 6 (actual)

## Conditions studied

- Carcinoma, Non-Small Cell Lung
- Squamous Cell Carcinoma of Head and Neck
- Esophageal Squamous Cell Carcinoma
- Gastric Adenocarcinoma
- Esophageal Adenocarcinoma
- Gastroesophageal Junction Adenocarcinoma

## Interventions

- **DRUG:** sigvotatug vedotin

## Key facts

- **NCT ID:** NCT06549816
- **Lead sponsor:** Seagen, a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-08-21
- **Primary completion:** 2025-11-18
- **Final completion:** 2025-11-18
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2025-12-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06549816

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06549816, "A Study of SGN-B6A in Chinese Participants With Advanced Solid Tumors". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT06549816. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*